bevacizumab + oxaliplatin + fluoropyrimidine

Bevacizumab + oxaliplatin + fluoropyrimidine is a combination chemotherapy regimen used primarily for the treatment of metastatic colorectal cancer and studied across advanced solid tumors, including neuroendocrine tumors. - **Bevacizumab** is a humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), thereby inhibiting tumor angiogenesis. - **Oxaliplatin** is a platinum-based chemotherapeutic that causes DNA crosslinking and apoptosis. - **Fluoropyrimidine** refers to a class of drugs (commonly 5-fluorouracil or capecitabine) that are antimetabolites, inhibiting thymidylate synthase and disrupting DNA synthesis. - The combination is the current standard of care for first- and second-line therapy in metastatic colorectal cancer, and may be used in specific advanced neuroendocrine tumors. - The regimen is typically administered intravenously in cycles, usually using modified FOLFOX (5-fluorouracil, folinic acid, oxaliplatin) or CAPOX/XELOX (capecitabine, oxaliplatin) together with bevacizumab. - The combination remains investigational or off-label for other solid tumor indications[1][3][5].

Brand names

AvastinEloxatinXeloda

Other names

bevacizumab plus oxaliplatin plus fluoropyrimidinebevacizumab + FOLFOXbevacizumab + XELOX